MedPath

Telios Pharma, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

27

Active:19
Completed:3

Trial Phases

3 Phases

Phase 1:18
Phase 2:7
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials

Phase 1
18 (66.7%)
Phase 2
7 (25.9%)
Not Applicable
1 (3.7%)
phase_1_2
1 (3.7%)

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

Phase 2
Recruiting
Conditions
Allergic Conjunctivitis
Interventions
Drug: Placebo
First Posted Date
2024-11-13
Last Posted Date
2024-11-13
Lead Sponsor
Telios Pharma, Inc.
Target Recruit Count
66
Registration Number
NCT06686472
Locations
🇺🇸

Telios Investigative Site, Memphis, Tennessee, United States

A Study Of TL-925 For The Treatment of AC

Phase 2
Completed
Conditions
Allergic Conjunctivitis
Interventions
Drug: Placebo
First Posted Date
2024-03-05
Last Posted Date
2024-07-03
Lead Sponsor
Telios Pharma, Inc.
Target Recruit Count
80
Registration Number
NCT06293820
Locations
🇺🇸

Andover Eye Associates, Andover, Massachusetts, United States

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Phase 2
Active, not recruiting
Conditions
Dry Eye Disease
Interventions
Other: Placebo
First Posted Date
2024-01-26
Last Posted Date
2024-07-10
Lead Sponsor
Telios Pharma, Inc.
Target Recruit Count
880
Registration Number
NCT06225973
Locations
🇺🇸

Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States

🇺🇸

Global Research Management, Glendale, California, United States

🇺🇸

Nvision - La Mesa, La Mesa, California, United States

and more 14 locations

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Phase 2
Recruiting
Conditions
Allergic Conjunctivitis
Interventions
Drug: Placebo
First Posted Date
2023-12-01
Last Posted Date
2023-12-01
Lead Sponsor
Telios Pharma, Inc.
Target Recruit Count
70
Registration Number
NCT06153342
Locations
🇺🇸

Andover Eye Associates, Andover, Massachusetts, United States

A Study of TL-925 as a Treatment for Dry Eye Disease

Phase 2
Completed
Conditions
Dry Eye Disease
Interventions
Drug: Placebo
First Posted Date
2023-02-27
Last Posted Date
2023-11-18
Lead Sponsor
Telios Pharma, Inc.
Target Recruit Count
107
Registration Number
NCT05745064
Locations
🇺🇸

Aesthetic Eye Care, Newport Beach, California, United States

🇺🇸

Vision Institute, Colorado Springs, Colorado, United States

🇺🇸

Michael Washburn Center for Ophthalmic Research, LLC., Indianapolis, Indiana, United States

and more 1 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.